ERBB2 and neoplasm: The ASCO/CAP guidelines [50] define HER2 overexpression as immunohistochemistry (IHC) 3 + or IHC 2 + with amplification by in situ hybridization, where the proportion of IHC 2 + tumor cells in HER2+ patients is significantly associated with treatment response [51].